NEW YORK (GenomeWeb) – BG Medicine today reported third quarter revenues of $334,000, down 52 percent from $695,000 in the third quarter of 2014.

The decline was due to a drop in product revenues from sales of the company's BGM Galectin-3 test, which fell to $274,000 in the quarter, down 59 percent from $669,000 in Q3 2014. Product fee revenues were up 57 percent to $60,000 compared to $26,000 in the year-ago period.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.